Print this page    •   Back to Web version of article

The Body Covers: The XIV International AIDS Conference

The XIV International AIDS Conference
Barcelona, Spain

July 7-12, 2002

The Body Covers:
The XIV International AIDS Conference
Barcelona, Spain

July 7-12, 2002

Overviews

Complete Index

Coverage From Other Sources

Audio and Video From Barcelona

Click here to see and hear highlights from the International AIDS Conference.

  • Former U.S. President Bill Clinton and former South African President Nelson Mandela close the XIV International AIDS Conference with moving speeches on shattering the stigma against HIV-positive people and moving forward to crush the epidemic.
  • View in-depth rundowns of the major events, revelations and developments from each day of the conference.
  • Zambia has made great strides in its efforts to prevent its country's youth from contracting HIV. Get the details on its successes from this Webcast.
  • Sit in on the July 10 announcement of a new global campaign to prevent mother-to-child transmission of HIV. The announcement includes speeches by several top researchers and politicians, including Allan Rosenfield, M.D., of Columbia University, and Helene Gayle, the director of HIV/AIDS and tuberculosis for the Bill & Melinda Gates Foundation.

  • Bill Clinton, U.S. Senator Bill Frist and U.S. Representative Nancy Pelosi speak in Barcelona about the role of political leadership in stemming the tide of HIV.

  • From his perch in South Africa, John Battersby, the editor of the Independent Newspapers Group, has watched the epidemic unfold in Africa from its infancy in the early 1980s. In this interview, he discusses his experience learning about, and covering, the spread of HIV across the continent.

  • July 11 featured a plenary session entitled "From Science into Action," which concentrated on practical ways that effective HIV treatments can be disseminated throughout the world. Click here to watch the Webcast of the event.
  • By 2010, experts say, AIDS will have left one out of every five African children without his or her parents. For more on the growing AIDS orphan crisis and on the constant debate over whether HIV prevention or treatment should be the higher priority, listen in.

  • In an up-close interview, Peter Piot, the executive director of UNAIDS, reveals what brought him to the front lines of the HIV/AIDS battle -- and why he decided to become involved with the epidemic in the first place.

  • Discussing prevention methods and treatment options for the developing world is great, but how are we actually going to pay for them? Watch UNAIDS' June 10 press conference on financing the global war against AIDS.

  • Judy Auerbach of the National Institutes of Health talks about the successes and challenges of modern HIV-prevention efforts.

  • Highlights:

    Barcelona had more than 10,000 presentations but we could cover only a fraction of these. So we asked Pablo Tebas, M.D. to give us an overview of what he took home from Barcelona.

    HAART has led to declines in the incidence of other malignancies such as Kaposi's sarcoma and non-Hodgkin's lymphoma, but its effect on HPV-associated anogenital cancers is unclear. Dr. Judith Aberg analyzes a recent study.

    We know that potent antiretroviral therapy will reduce transmission from a woman to her HIV-positive baby. But are studies in the developing world that give therapy to the mother during labor without intention of continuing afterwards ethical? Dr. Judith Aberg looks at one such study.

    Quite a few presentations at this year's conference revolved around tenofovir, as researchers reported on its effectiveness in a wide variety of treatment situations. One widely discussed study compared a drug regimen with tenofovir to one with d4T, and found that tenofovir worked just as well, but with fewer side effects. More from Cal Cohen, M.D.

    Hope for negative women who want to have a child with an HIV-positive man! In over 4,000 inseminations in more than 1,500 couples there were no transmissions of HIV. Dr. Judy Aberg reports on this presentation.

    Dramatic results for patients with both HIV and hepatitis B using tenofovir. Read Andrew Pavia's coverage of this important study.

    Results from the important T-20 studies with treatment-experienced patients are in and it looks like it will be approved soon. Pablo Tebas, M.D. reports.

    A Boston-area HIV patient whose immune system had remarkably reconstituted suffered a rapid clinical decline after he became superinfected with a related strain of HIV. Keith Henry, M.D. provides the details of Dr. Bruce Walker's findings.

    Research is still plodding ahead on the different ways that treatment interruptions may improve care. Read Cal Cohen's update from Barcelona on the very latest research.

    From Marrakech to Doha: Pablo Tebas, M.D. covers an informative crash course on patent law.

    The results of a recent trial add to the rationale of a more conservative approach to treatment, in which the initiation of therapy is delayed until CD4+ cell counts consistently drop below 350. Read Pablo Tebas, M.D.'s coverage for more details.

    Protease inhibitors are taking a big hit as first-line agents in the treatment of antiretroviral-naïve patients. Pablo Tebas, M.D. says the studies are finally catching up to clinical practice. Click here to read more.

     
    The Body's HIV Experts Covering AIDS 2002:
     
    Judith Aberg, M.D. Cal Cohen, M.D., M.S. Edwin DeJesus, M.D. Robert J. Frascino, M.D.
    Judith Aberg, M.D. Cal Cohen, M.D., M.S. Edwin DeJesus, M.D. Robert J. Frascino, M.D.
     
    Keith Henry, M.D. Mark Holodniy, M.D., F.A.C.P., C.I.C. Andrew T. Pavia, M.D. Paul Sax, M.D.
    Keith Henry, M.D. Mark Holodniy, M.D., F.A.C.P., C.I.C. Andrew T. Pavia, M.D. Paul Sax, M.D.
      Pablo Tebas, M.D. Benjamin Young, M.D.  
      Pablo Tebas, M.D. Benjamin Young, M.D., Ph.D.  
     
    AIDS 2002 was held from July 7-12, 2002 in Barcelona, Spain. The Body Pro's next-day conference coverage is reported exclusively by some of the most outstanding HIV specialists in the U.S. Funding for this conference coverage at The Body Pro is provided, in part, by unrestricted educational grants from Boehringer Ingelheim Pharmaceuticals, BTG Pharmaceuticals, Gilead, GlaxoSmithKline and Ortho Biotech. All coverage is © 2002 Body Health Resources Corporation.
     


    Please note: Knowledge about HIV changes rapidly. Note the date of this summary's publication, and before treating patients or employing any therapies described in these materials, verify all information independently. If you are a patient, please consult a doctor or other medical professional before acting on any of the information presented in this summary. For a complete listing of our most recent conference coverage, click here.

    Advertisement




    This article was provided by TheBodyPRO.com. Copyright Body Health Resources Corporation. All rights reserved.

    You can find this article online by typing the following address into your Web browser:
    http://www.thebody.com/content/art16419.html

    Please Note: Knowledge about HIV changes rapidly. Note the date of this article's publication, and before treating patients or employing any therapies described in these materials, verify all information independently. If you are a patient, please consult a doctor or other medical professional before acting on any of the information presented in this article.

    General Disclaimer: The Body is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through The Body should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your healthcare provider.